Figure 1.

A, Cumulative proportion of patients who had severe status of COVID‐19 vs nonsevere ones, by day after illness onset. B, Cumulative proportion of patients who started antiviral treatment less than 5 days vs more than or equal to 5 days, by day after illness onset. C, Cumulative proportion of patients who received lopinavir/ritonavir +interferon (IFN) combination therapy as the initial antiviral treatment vs lopinavir/ritonavir monotherapy, by day after illness onset. D, Cumulative proportion of patients who received lopinavir/ritonavir + IFN combination therapy as the initial antiviral treatment vs lopinavir/ritonavir + IFN + arbidol combination therapy, by day after illness onset. COVID‐19, coronavirus disease‐2019